Predicting Post-Hepatectomy Liver Failure with the PILOT Architecture: Integrating Liver Regeneration Biomarkers and Time-Phased Machine Learning
Posted inAI General Surgery news

Predicting Post-Hepatectomy Liver Failure with the PILOT Architecture: Integrating Liver Regeneration Biomarkers and Time-Phased Machine Learning

The novel PILOT machine learning architecture integrates time-phased perioperative data and regeneration-associated biomarkers to predict post-hepatectomy liver failure within six hours of surgery, significantly outperforming traditional clinical models and enabling early personalized risk stratification.
Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial
Posted inCardiology news

Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial

While the ODYSSEY-HCM trial missed its primary functional endpoints, a new exploratory analysis reveals that mavacamten significantly reduces NT-proBNP and hs-cTnI levels in patients with nonobstructive hypertrophic cardiomyopathy, suggesting a potent biological effect on myocardial wall stress and chronic injury.
Beyond Troponin: Cardiac Myosin-Binding Protein C Accelerates NSTEMI Diagnosis and Emergency Department Triage
Posted inCardiology Emergency Medicine news

Beyond Troponin: Cardiac Myosin-Binding Protein C Accelerates NSTEMI Diagnosis and Emergency Department Triage

A secondary analysis of the APACE study demonstrates that Cardiac Myosin-Binding Protein C (cMyC) significantly improves NSTEMI diagnosis, particularly in early presenters. Integrating cMyC with high-sensitivity troponin into a dual-biomarker strategy doubles triage efficacy without compromising safety, offering a robust tool for busy clinical settings.
Lower Posttreatment Amyloid Predicts Slower Clinical Decline and Reduced Tau/Glial Biomarkers After Donanemab: Secondary Analysis of TRAILBLAZER‑ALZ 2
Posted inNeurology news

Lower Posttreatment Amyloid Predicts Slower Clinical Decline and Reduced Tau/Glial Biomarkers After Donanemab: Secondary Analysis of TRAILBLAZER‑ALZ 2

A secondary analysis of TRAILBLAZER‑ALZ 2 found that lower posttreatment amyloid plaque levels after donanemab correlate strongly with less clinical decline and reductions in plasma p‑tau217, p‑tau181, and GFAP over 76 weeks, supporting plaque removal as a likely mechanism of benefit.
Extratemporal epilepsy, obesity and male sex predict SUDEP risk in drug‑resistant focal epilepsy: clinical insights from the REPO2MSE prospective case‑control study
Posted inNeurology news

Extratemporal epilepsy, obesity and male sex predict SUDEP risk in drug‑resistant focal epilepsy: clinical insights from the REPO2MSE prospective case‑control study

A multicentre prospective nested case‑control analysis (REPO2MSE) identifies extratemporal seizure onset, BMI ≥30, male sex, and predominantly nocturnal seizures as independent SUDEP risk factors in drug‑resistant focal epilepsy; peri‑ictal hypoxaemia and focal‑to‑bilateral tonic‑clonic seizure frequency were not significant.